L E K A R N I Š T V O 2 / 2 0 16
22
Viri: 1. Cancer in Slovenia 2012. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2015. 2. Hočevar M et al. Smernice in klinična pot za obravnavo bolnikov z melanomom, Onkološki inštitut Ljubljana, januar 2010 (http://www.onko-i.si/fileadmin/_migrated/content_uploads/Melanom_smernice_in_klinicna_pot_2010.pdf ). 3. Kirkwood J, Agarwala S. Systemic cytotoxic and biologic therapy melanoma. In: Cancer principles and practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 1993. p. 1-16. 4. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim Biophys Acta 2007;1773:1263-1284. 5. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947. 6. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and I3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul 2006;46:249-279. 7. Claperón A, Therrien M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 2007;26:3143-3158. 8. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(suppl 5):v126-v132. 9. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 2.2016. 10. Povzetek glavnih značilnosti zdravila Zelboraf, dostopano maj 2016 na http://www.ema.europa.eu/docs/sl_SI/ document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf 11. McArthur G, Chapman P, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, openlabel study. Lancet Oncol 2014; 15:323–332. 12. Povzetek glavnih značilnosti zdravila Tafinlar, dostopano maj 2016 na http://www.ema.europa.eu/docs/sl_SI/ document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf 13. Larkin J, Ascierto P, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New Eng J Med 2014;371(20):1867-1876. 14. Larkin J, Yan Y, McArthur G, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 2015; 33(15, suppl May 20):9006. 15. McArthur G, Larkin J, Dreno B, et al. Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. Eur J Cancer 2015; 51:S722-S723. 16. Atkinson V, Larkin J, McArthur G, et al. Improved overal survival (OS) with cobimetinib (COBI) + vemurafenib (V) in advanced BRAF-mutated melanoma and biomerker correlates of efficacy. Late Breaking Abstract predstavljen na Society of Melanoma Research 2015, dostopen na http://www.melanomacongress.com/docs/ SMR_2015_Congress_Late_Breaking_Abstracts.pdf 17. Povzetek glavnih značilnosti zdravila Cotellic, dostopano maj 2016 na http://www.ema.europa.eu/docs/sl_SI/ document_library/EPAR_-_Product_Information/human/003960/WC500198563.pdf 18. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15:954-965. 19. Pavlick A, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol 2015; 33(15, suppl May 20):9020. 20. Lewis K, Ribas A, Gonzalez R, et al. Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: results from the BRIM7. Eur J Cancer 2015; 51(suppl 3):S679. 21. Dreno B, Bartley K, Ascierto P, et al. Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). J Clin Oncol 2015; 33(15, suppl May 20):9021.